Actelion Ltd (ALIOF) 164.2900 $ALIOF
Is ACTELION (ALIOF) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:35AM CDT
ACTELION (ALIOF) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
Intercept (ICPT) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:32AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.14 per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.76.
AGEN: 6.22 (+0.28), BIIB: 315.00 (+1.06), ICPT: 162.99 (+5.30)
Merrimack (MACK) Q2 Loss Wider than Expected, Sales Top
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 3:02PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 40 cents per share in the second quarter of 2016, wider than the Zacks Consensus Estimate of 34 cents.
MACK: 5.20 (+0.02)
Exelixis (EXEL) Posts Narrower Loss in Q2, Beats on Revenues
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 2:52PM CDT
Exelixis, Inc. (EXEL) posted a second-quarter 2016 loss of 16 cents, narrower than both the Zacks Consensus Estimate of 27 cents and the year-ago loss of 22 cents
BIIB: 315.00 (+1.06), EXEL: 10.66 (unch)
Why ACTELION (ALIOF) Could Be an Impressive Growth Stock
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:37AM CDT
ACTELION can captivate investors' attention and produce gains, being well positioned for future earnings growth.
3 Dirt-Cheap Biotech Stocks To Buy
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 8:17AM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Sometimes stocks sell down to prices that look too good to be true, but just because a company appears cheap doesn't mean that its a good value. For a company to be a bargain that's really worth buying, there needs...
ENDP: 24.16 (-0.02), GILD: 79.84 (+0.18), MRK: 63.35 (-0.28), UTHR: 125.19 (+0.86)
Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved
Globe Newswire - Wed May 04, 5:00AM CDT
Actelion Pharmaceuticals Ltd / Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
United (UTHR) Stock Declines Despite Q1 Earnings Beat
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 10:54AM CDT
Although United Therapeutics (UTHR) delivered an earnings beat, shares were down on the revenue miss.
EBS: 26.87 (-0.73), UTHR: 125.19 (+0.86), AEGR: 1.57 (+0.02)
Very strong performance continues in the first quarter of 2016 - driven by outcome-based PAH portfolio
Globe Newswire - Thu Apr 21, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Very strong performance continues in the first quarter of 2016 - driven by outcome-based PAH portfolio . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Clovis Hits 52-week Low Post Rociletinib Briefing Documents
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 2:45PM CDT
Clovis Oncology's (CLVS) shares touched a 52-week low with the FDA raising concerns related to the lung cancer treatment, rociletinib, in its briefing documents.
EBS: 26.87 (-0.73), CLVS: 16.87 (+0.66), ANIK: 48.79 (-0.15)
Ionis Tanks, FDA Clinical Hold on IONIS-TTRRx Phase III Study
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 3:40PM CDT
Ionis Pharmaceuticals' (IONS) shares plunged 11% after the FDA placed a clinical hold on the phase III CARDIO-TTR study on IONIS-TTRRx.
BIIB: 315.00 (+1.06), GSK: 44.51 (+0.34), IONS: 35.00 (-0.03)
Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 2:35PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA's Gastrointestinal Drugs Advisory Committee has voted unanimously in favor of the company's lead pipeline candidate, Ocaliva.
ARQL: 1.49 (-0.08), SCMP: 11.61 (-0.16), ICPT: 162.99 (+5.30)
Illumina Unveils BaseSpace Suite, Boosts Precision Medicine
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 12:55PM CDT
Illumina, Inc. (ILMN) recently launched its BaseSpace Informatics suite to facilitate precision medicine and genomics research.
ILMN: 166.99 (-1.03), AMAG: 24.44 (+1.35), ANIK: 48.79 (-0.15)
Seres Therapeutics (MCRB) in Focus: Stock Up 5.5% in Session
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:35AM CDT
Seres Therapeutics, Inc. (MCRB) was a big mover last session, as the company saw its shares rise around 6% on the day.
MCRB: 10.57 (+0.04)
Ironwood Slumps, Halts Development of Gastroparesis Drug
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 9:10AM CDT
Ironwood Pharmaceuticals (IRWD) plans to discontinue the development of IW-9179 for diabetic gastroparesis after unfavorable phase IIa study results; shares fall.
IRWD: 13.36 (+0.02), EBS: 26.87 (-0.73), AMAG: 24.44 (+1.35)
Actelion issues invitation to 2016 Annual General Meeting of Shareholders
Globe Newswire - Wed Apr 06, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Actelion issues invitation to 2016 Annual General Meeting of Shareholders . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
AbbVie Up, Wins CHMP Backing for Humira's Expanded Use
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 10:20AM CDT
AbbVie Inc. (ABBV) announced that the EMA's CHMP has rendered an opinion in favor of expanding Humira's label in the EU.
EBS: 26.87 (-0.73), ABBV: 67.15 (-0.04), AMAG: 24.44 (+1.35)
Abeona Therapeutics (ABEO) Jumps: Stock Rises 6.4%
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 7:40AM CDT
Abeona Therapeutics Inc. (ABEO) saw its shares rise above 6% in the last trading session.
ABEO: 3.58 (-0.03)
Bristol-Myers Gets CHMP Backing for Opdivo's Expanded Use
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 3:10PM CDT
Bristol-Myers' (BMY) Opdivo gets CHMP backing for label expansion of Opdivo in combination with Yervoy for advanced (unresectable or metastatic) melanoma.
AMAG: 24.44 (+1.35), BMY: 60.83 (+0.20), ANIK: 48.79 (-0.15)
Regeneron, Sanofi Up, Eczema Drug Tops Phase III Studies
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 2:40PM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi's atopic dermatitis candidate dupilumab scores in phase III studies; shares up.
AMAG: 24.44 (+1.35), SNY: 40.16 (unch), REGN: 421.54 (+0.19)
Is ACTELION (ALIOF) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:35AM CDT
ACTELION (ALIOF) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
Intercept (ICPT) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:32AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.14 per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.76.
AGEN: 6.22 (+0.28), BIIB: 315.00 (+1.06), ICPT: 162.99 (+5.30)
Merrimack (MACK) Q2 Loss Wider than Expected, Sales Top
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 3:02PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 40 cents per share in the second quarter of 2016, wider than the Zacks Consensus Estimate of 34 cents.
MACK: 5.20 (+0.02)
Exelixis (EXEL) Posts Narrower Loss in Q2, Beats on Revenues
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 2:52PM CDT
Exelixis, Inc. (EXEL) posted a second-quarter 2016 loss of 16 cents, narrower than both the Zacks Consensus Estimate of 27 cents and the year-ago loss of 22 cents
BIIB: 315.00 (+1.06), EXEL: 10.66 (unch)
Why ACTELION (ALIOF) Could Be an Impressive Growth Stock
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:37AM CDT
ACTELION can captivate investors' attention and produce gains, being well positioned for future earnings growth.
3 Dirt-Cheap Biotech Stocks To Buy
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 8:17AM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Sometimes stocks sell down to prices that look too good to be true, but just because a company appears cheap doesn't mean that its a good value. For a company to be a bargain that's really worth buying, there needs...
ENDP: 24.16 (-0.02), GILD: 79.84 (+0.18), MRK: 63.35 (-0.28), UTHR: 125.19 (+0.86)
Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved
Globe Newswire - Wed May 04, 5:00AM CDT
Actelion Pharmaceuticals Ltd / Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
United (UTHR) Stock Declines Despite Q1 Earnings Beat
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 10:54AM CDT
Although United Therapeutics (UTHR) delivered an earnings beat, shares were down on the revenue miss.
EBS: 26.87 (-0.73), UTHR: 125.19 (+0.86), AEGR: 1.57 (+0.02)
Very strong performance continues in the first quarter of 2016 - driven by outcome-based PAH portfolio
Globe Newswire - Thu Apr 21, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Very strong performance continues in the first quarter of 2016 - driven by outcome-based PAH portfolio . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Clovis Hits 52-week Low Post Rociletinib Briefing Documents
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 2:45PM CDT
Clovis Oncology's (CLVS) shares touched a 52-week low with the FDA raising concerns related to the lung cancer treatment, rociletinib, in its briefing documents.
EBS: 26.87 (-0.73), CLVS: 16.87 (+0.66), ANIK: 48.79 (-0.15)
Ionis Tanks, FDA Clinical Hold on IONIS-TTRRx Phase III Study
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 3:40PM CDT
Ionis Pharmaceuticals' (IONS) shares plunged 11% after the FDA placed a clinical hold on the phase III CARDIO-TTR study on IONIS-TTRRx.
BIIB: 315.00 (+1.06), GSK: 44.51 (+0.34), IONS: 35.00 (-0.03)
Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 2:35PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA's Gastrointestinal Drugs Advisory Committee has voted unanimously in favor of the company's lead pipeline candidate, Ocaliva.
ARQL: 1.49 (-0.08), SCMP: 11.61 (-0.16), ICPT: 162.99 (+5.30)
Illumina Unveils BaseSpace Suite, Boosts Precision Medicine
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 12:55PM CDT
Illumina, Inc. (ILMN) recently launched its BaseSpace Informatics suite to facilitate precision medicine and genomics research.
ILMN: 166.99 (-1.03), AMAG: 24.44 (+1.35), ANIK: 48.79 (-0.15)
Seres Therapeutics (MCRB) in Focus: Stock Up 5.5% in Session
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:35AM CDT
Seres Therapeutics, Inc. (MCRB) was a big mover last session, as the company saw its shares rise around 6% on the day.
MCRB: 10.57 (+0.04)
Ironwood Slumps, Halts Development of Gastroparesis Drug
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 9:10AM CDT
Ironwood Pharmaceuticals (IRWD) plans to discontinue the development of IW-9179 for diabetic gastroparesis after unfavorable phase IIa study results; shares fall.
IRWD: 13.36 (+0.02), EBS: 26.87 (-0.73), AMAG: 24.44 (+1.35)
Actelion issues invitation to 2016 Annual General Meeting of Shareholders
Globe Newswire - Wed Apr 06, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Actelion issues invitation to 2016 Annual General Meeting of Shareholders . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
AbbVie Up, Wins CHMP Backing for Humira's Expanded Use
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 10:20AM CDT
AbbVie Inc. (ABBV) announced that the EMA's CHMP has rendered an opinion in favor of expanding Humira's label in the EU.
EBS: 26.87 (-0.73), ABBV: 67.15 (-0.04), AMAG: 24.44 (+1.35)
Abeona Therapeutics (ABEO) Jumps: Stock Rises 6.4%
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 7:40AM CDT
Abeona Therapeutics Inc. (ABEO) saw its shares rise above 6% in the last trading session.
ABEO: 3.58 (-0.03)
Bristol-Myers Gets CHMP Backing for Opdivo's Expanded Use
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 3:10PM CDT
Bristol-Myers' (BMY) Opdivo gets CHMP backing for label expansion of Opdivo in combination with Yervoy for advanced (unresectable or metastatic) melanoma.
AMAG: 24.44 (+1.35), BMY: 60.83 (+0.20), ANIK: 48.79 (-0.15)
Regeneron, Sanofi Up, Eczema Drug Tops Phase III Studies
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 2:40PM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi's atopic dermatitis candidate dupilumab scores in phase III studies; shares up.
AMAG: 24.44 (+1.35), SNY: 40.16 (unch), REGN: 421.54 (+0.19)
